Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway

Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway

Research on repurposing the old alcohol-aversion drug disulfiram (DSF) for cancer treatment has identified inhibition of NPL4, an adaptor of the p97/VCP segregase essential for turnover of proteins involved in multiple pathways, as an unsuspected cancer cell vulnerability. While we reported that NPL...

Full description

Bibliographic Details
Main Authors: Dusana Majera, Zdenek Skrott, Katarina Chroma, Joanna Maria Merchut-Maya, Martin Mistrik, Jiri Bartek
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cells
Subjects:
targeted cancer therapy
disulfiram
npl4
replication stress
dna damage
brca1
brca2
atr pathway
Online Access:https://www.mdpi.com/2073-4409/9/2/469

Internet

https://www.mdpi.com/2073-4409/9/2/469

Similar Items